Harmony Biosciences Unveils Positive Phase 1 Data for Orexin Agonist BP-205, Plans Mid-2027 Phase 2
HRMY sits 45% above its 52-week low of $25.52 on elevated volume (2.3× avg).
Summary
Harmony Biosciences reported favorable Phase 1 single ascending dose data for BP-205, its orexin-2 receptor agonist, showing good pharmacokinetics and safety. The company plans to initiate Phase 2 studies in multiple CNS indications starting mid-2027. This expands the pipeline beyond the core WAKIX franchise, which just posted record Q2 revenue of $261.3M. The news follows the recent CFO departure and insider selling, but the pipeline progress offers a new growth narrative. The stock rose 8% on the earnings beat and pipeline update, with analysts raising price targets.
At the time of this announcement, HRMY was trading at $37.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $25.52 to $40.87. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.